Skip to content
HowShorted

Keros Therapeutics, Inc. short interest in 2023

In 2023, Keros Therapeutics, Inc.'s disclosed short interest ran from 2.17% of shares outstanding on 13 Jan 2023 to 4.58% on 29 Dec 2023, a change of +2.41 percentage points. The year's high was 4.88% on 15 Dec 2023 and its low 2.07% on 28 Apr 2023, averaging 3.30% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.46 days on 14 Jul 2023. Full history: Keros Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Keros Therapeutics, Inc. in 2023

2023 in figures

Start of year
2.17% (13 Jan 2023)
End of year
4.58% (29 Dec 2023)
Change
+2.41 pp
High
4.88% (15 Dec 2023)
Low
2.07% (28 Apr 2023)
Average
3.30%
Highest days to cover
9.46 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Keros Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.17%3.58
31 Jan 20232.33%2.73
15 Feb 20232.22%3.13
28 Feb 20232.14%4.57
15 Mar 20232.56%1.7210-K filed, results (8-K)
31 Mar 20232.61%4.18
14 Apr 20232.24%3.37
28 Apr 20232.07%5.32
15 May 20232.32%4.0410-Q filed, results (8-K)
31 May 20232.78%3.88
15 Jun 20232.96%2.61
30 Jun 20232.96%2.63
14 Jul 20233.29%9.46
31 Jul 20233.46%5.15
15 Aug 20233.79%8.2410-Q filed, results (8-K)
31 Aug 20233.83%7.15
15 Sep 20233.97%4.97
29 Sep 20234.46%6.31
13 Oct 20234.28%5.37
31 Oct 20234.30%6.78
15 Nov 20234.08%3.7410-Q filed, results (8-K)
30 Nov 20234.82%6.18
15 Dec 20234.88%2.88
29 Dec 20234.58%3.81

See also: Keros Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.